Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.
Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice
Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, July 15, 2026, 1:00-2:00 PM ET
Hear an expert discuss how to integrate Kappa and Lambda in situ hybridization testing into your standard hematopathology workflow to accurately assess B-cell and plasma cell clonality. You will also gain the skills to recognize testing pitfalls in challenging reactive versus neoplastic proliferations and apply ancillary tools to resolve complex cases.
Webinar presenter Xiaojun Wu, MD, PhD, Assistant professor, Director of Hematopathology Section at NCR of Johns Hopkins Medicine Department of Pathology, SOM at Johns Hopkins University
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
November 2024—New this month from CAP Publications is the CAP Practical Guide to Gynecologic Cytopathology—Morphology, Management, and Molecular Methods, second edition. Its 15 chapters cover squamous and glandular epithelial abnormalities, anal cytology, benign changes and mimics of premalignant and malignant epithelial lesions, and much more. In this issue we provide part of the chapter on look-alikes and morphologic spectrums of change.
November 2024—Acute myeloid leukemia (AML) stands out as the most prevalent form of leukemia, constituting 80 percent of cases in adults and 15 to 20 percent in children. It arises from the clonal proliferation of genetically aberrant hematopoietic stem and progenitor cells, impeding normal hematopoiesis. AML is linked to a variable number of cytogenetic abnormalities, and the identification of these abnormalities holds crucial implications, given their association with an elevated risk of inherited AML.
Lab data displays, IT demands that outrun resources, at-home test results, and HL7 are some of what came up on Sept. 20 when CAP TODAY publisher Bob McGonnagle spoke online with pathologists and industry executives about laboratory information systems. “It’s fire and forget,” said Ulysses G. J. Balis, MD, of the University of Michigan, about the lack of feedback from the EHR that a clinician has seen and understood a complex result. “Loss to follow-up is a real possibility,” he said.
November 2024—Members of the CAP Foundation Global Pathology Committee and the CAP Cancer Committee collaborated to develop a three-part webinar series on how to use the CAP cancer protocols. The webinars were directed to international pathologists, particularly those in low- and middle-income countries.
November 2024—There’s a shortage of physicians in the U.S.—across specialty areas and including pathology—and the reaction has been rather predictable: nonphysicians are pushing hard to fill those voids. Scope of practice is a major issue facing physicians today, and pathologists are no exception. In other specialties, we’ve seen nurse practitioners and physician assistants step up to take on more and more responsibilities that were once reserved for physicians. For certain tasks and under the supervision of a physician, this is not only appropriate but welcome. In pathology we have pathologist assistants performing valuable tasks in support of pathologists with a real impact on patient care. All of these nonphysicians are important for patient care and for easing the burden on physicians who are stretched too thin.
November 2024—Pathology training programs are meant to prepare trainees for the workforce by imparting medical knowledge and developing skills in diagnostic interpretation in anatomic pathology. Yet transitioning to the workforce can be challenging for some new graduates. To address this, many training programs have begun teaching management and leadership skills that are required on the job. In addition, the College of American Pathologists New in Practice Committee developed online educational material to provide practical advice for those starting their pathology careers.
November 2024—Inactivating alterations in switch/sucrose nonfermentable (SWI/SNF) chromatin remodeling complex subunits have been described in multiple tumor types. Recent studies focused on SMARC subunits of this complex to explain their relationship with tumor characteristics and therapeutic opportunities. Pancreatic cancer with these alterations has not been well studied, although isolated cases of undifferentiated carcinomas have been reported.
November 2024—Many people with an intellectual disability do not receive a molecular diagnosis following genetic testing. While 1,427 genes have been confidently identified as etiological for an intellectual disability (ID), all but nine of them are protein coding. To identify noncoding etiologies of ID, the authors conducted a genetic association analysis using whole genome sequencing data on 77,539 participants in the 100,000 Genomes Project. The study included 29,741 probands and 4,782 affected relatives assigned by expert clinicians to one or more of 220 specific disease classes encompassing a wide range of pathologies.
NOVEMBER 2024 Q. Our laboratory was cited for a deficiency because the manufacturer and methodology of our tumor marker assay was not available to clinicians. What is the reasoning behind this requirement? Read answer.
Q. For patients who have a hematocrit level greater than 55 percent, is it okay to use a CBC (hematocrit) that was not collected at the same time as the citrate sample? For example, can we use a CBC collected within 24 hours for an inpatient and a CBC from a previous visit for an outpatient? Read answer.
November 2024—A picture may be worth a thousand words, but a conventional two-dimensional photograph of a surgical specimen can convey only so much information to a pathologist or surgeon. Overall geometry and margin status are difficult to interpret from static, single-perspective images.
